Hubei Biocause Heilen Pharmaceutical Co., Ltd. Class A

Hubei Biocause Heilen Pharmaceutical Co., Ltd. Class A

SSZSE:301211
10.15
CNY
-0.33
(-3.15%)
0.13EPS
101.45P/E
5.30BMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.23
1.68
2.12
1.89
1.74
1.24
1.58
1.07
1.04
1.14
Basic EPS, GAAP
0.03
0.16
0.32
0.53
0.39
0.3
0.42
0.22
0.08
0.13
Free Cash Flow per Basic Share
-0.26
0.17
1.09
0.34
0.33
0.42
-0.12
-0.16
-0.1
- -
Dividend per Share
0.01
0.02
0.01
0.01
- -
0.17
0.23
0.33
0.16
- -
Book Value per Share
0.76
0.91
1.56
2.24
5.32
5.45
5.64
5.53
5.44
5.48
Tangible Book Value per Share
0.62
0.81
1.43
2.04
5.16
5.28
5.47
5.37
5.27
5.31
Basic Weighted Avg Shares
298
308
312
314
311
415
419
416
436
428
Sales/Revenue/Turnover
366
517
660
593
541
515
663
446
453
489
Operating Margin (%)
9.94
21.97
32.38
34.28
24.28
15.87
22.61
7.23
1.63
6.17
Depreciation Expense
16
16
22
18
19
22
22
25
43
- -
Net Income, GAAP
10
48
100
168
122
126
176
92
35
54
Effective Tax Rate (%)
11.71
14.2
14.92
15.38
12.6
14.68
13.16
8.83
15.39
12.03
Profit Margin (%)
2.8
9.23
15.19
28.35
22.5
24.43
26.56
20.53
7.7
10.97
Working Capital
176
361
322
505
2,026
2,018
1,924
1,710
1,677
1,686
LT Debt
41
111
- -
- -
- -
6
5
4
2
- -
Total Equity
308
400
488
700
2,223
2,277
2,357
2,310
2,273
2,288
Return on Invested Capital (%)
- -
21.02
38.38
28.63
8.34
5.61
7.64
3.93
1.54
2.36
Return on Capital (%)
- -
6.84
6.37
29.09
8.32
5.6
7.59
3.93
1.53
2.36
Return on Common Equity (%)
- -
18.23
25.9
28.28
8.32
5.59
7.6
3.92
1.52
2.36

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
418
418
418
Market Capitalization
5,028
4,727
5,304

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,792
1,785
1,777
Cash, Cash Equivalents & STI
1,540
1,540
1,515
Accounts Receivable, Net
72
57
56
Inventories
126
139
141
Total Current Liabilities
104
101
91
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
43.95%
-1.58%
Free Cash Flow
- -
-11.93%
-34.49%
Net Income, GAAP
- -
-18.82%
-61.87%
Sales/Revenue/Turnover
- -
-3.18%
1.67%
Total Cash Common Dividend
- -
- -
-47.92%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
138
104
92
112
446
2025
114
120
- -
134
453
2026
120
127
107
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.09
0.07
0.01
0.04
0.22
2025
0.02
0.02
- -
0.03
0.08
2026
0.02
0.05
0.02
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.33
2025
- -
- -
- -
- -
0.16
2026
- -
- -
- -
- -
- -

Company Description

CEO
Qun Liang
Full Time Employees
987
Sector
Health technology
Industry
Pharmaceuticals: major
Address
122-132 Yangwan Road Jingmen HB China 448000
IPO Date
Dec 22, 2021
Business
Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of chemical raw materials, including intermediates, and pharmaceutical products. The company’s core product portfolio includes active pharmaceutical ingredients (APIs) such as non-steroidal anti-inflammatory raw materials ibuprofen and dexibuprofen; cardiovascular raw materials torasemide and milrinone; antitumor raw materials including abiraterone acetate and fludarabine phosphate; anticholinergic agent granisetron hydrochloride; as well as pharmaceutical preparations like torasemide tablets and ibuprofen granules. The company also produces chemical products including dimethyl ether gas and a-chloropropionyl chloride and operates contract development and manufacturing services (CDMO) allowing for customized R&D and production based on client requirements. Its products are exported to over 85 countries globally, including regulated markets in the USA and EU. Founded in 1995 and headquartered in Jingmen, Hubei Province, China, the company operates two API production sites and an R&D center, passing multiple inspections and approvals from the US FDA and EU GMP authorities. Recent developments include the launch of ibuprofen sustained-release capsules, which obtained pharmaceutical registration certification from China’s National Medical Products Administration, representing an expansion in its product formulation offerings. The company maintains strategic positioning in pharmaceuticals, chemicals, and new energy fuel sectors and has seen notable stock performance growth amid ongoing operational challenges reflected in recent financial results. It remains recognized as a high-tech enterprise in Hubei Province and among China’s top 20 CDMO enterprises. Hubei Biocause Heilen Pharmaceutical Co., Ltd. continues to focus on diversifying its product range within cardiovascular, anti-inflammatory, antitumor, and anti-infective therapeutic categories, serving both domestic and international markets with a comprehensive pipeline of APIs, intermediates, tablets, granules, and capsules alongside contract manufacturing services. Its ongoing regulatory approvals and product innovations underpin its competitive position in the pharmaceutical manufacturing sector.